dabigatran has been researched along with Pneumonia, Viral in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
| Eikelboom, JW; Eriksson, N; Ezekowitz, MD; Granger, CB; Hijazi, Z; Lindbäck, J; Lopes, RD; Oldgren, J; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
1 trial(s) available for dabigatran and Pneumonia, Viral
| Article | Year |
|---|---|
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
Topics: Aged; Angiotensin-Converting Enzyme 2; Antithrombins; Atrial Fibrillation; Betacoronavirus; Biomarkers; Cohort Studies; Coronavirus Infections; COVID-19; Dabigatran; Female; Humans; Male; Middle Aged; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazoles; Pyridones; Risk Factors; SARS-CoV-2; Stroke; Warfarin | 2020 |
1 other study(ies) available for dabigatran and Pneumonia, Viral
| Article | Year |
|---|---|
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |